SPONSORED:

Senate Health Committee chair asks Cuomo, Newsom to 'stop second guessing' FDA on vaccine efficacy

Sen. Lamar AlexanderAndrew (Lamar) Lamar AlexanderMcConnell chokes up saying goodbye to 'friend' Lamar Alexander in floor speech Mark Kelly sworn in to Senate seat Longtime GOP lawmaker urges Senate to restore itself in farewell speech MORE (R-Tenn.), chairman of the Senate Health Committee, on Saturday issued a call for New York Gov. Andrew CuomoAndrew CuomoBipartisan governors call on Congress to pass coronavirus relief package Hundreds protest over NY bar owners arrested for coronavirus violations The Hill's Morning Report - Presented by Mastercard - Dem leaders back smaller COVID-19 relief bill as pandemic escalates MORE (D) and California Gov. Gavin NewsomGavin NewsomNIH director implores religious leaders to close places of worship amid COVID-19 surge The Hill's Morning Report - Presented by Mastercard - Congress inches closer to virus relief deal Democratic figures accused of hypocrisy on COVID-19 precautions MORE (D) to “stop second guessing” analysis by scientists on the effectiveness of COVID-19 vaccines after the governors announced the creation of their own independent review boards. 

“The career scientists at the FDA set strict standards for safety and efficacy for COVID-19 vaccines,” Alexander said in a press release. “Every day Americans take the word of these scientists’ approval of safety and efficacy when we purchase 3.8 billion prescriptions each year.”

“Undermining the FDA’s gold standard of safety and efficacy by setting up state vaccine review panels could delay approval, discourage Americans from taking the vaccine, and cost lives,” Alexander continued. 

ADVERTISEMENT

The senator added in his statement that he hopes “these Democratic Governors would instead focus their time and resources on planning to distribute the vaccine, and improving testing and contact tracing with the resources Congress has provided, rather than second guessing the efforts of FDA scientists.”

The statement comes after Newsom announced in a press conference Monday that California is planning to review federally approved coronavirus vaccines independently before distributing them to residents. 

"The question I often get is 'Are you going to take someone’s word for it?' Of course, we don’t take anyone's 'word for it,'" Newsom said. "We will do our own independently reviewed process with our world-class experts."

Last month, Cuomo announced plans for a similar New York board that would independently review FDA-approved vaccines. 

Michigan, West Virginia and Washington, D.C., are also in the early stages of creating independent vaccine boards amid concerns that President TrumpDonald John TrumpAppeals court OKs White House diverting military funding to border wall construction Pentagon: Tentative meeting between spy agencies, Biden transition set for early next week Conservative policy director calls Section 230 repeal an 'existential threat' for tech MORE may be politically interfering with the FDA vaccine approval process as the administration pushes to get a vaccine ready as soon as possible with its Operation Warp Speed. 

ADVERTISEMENT

However, Alexander said in his statement Saturday that he had urged White House chief of staff Mark MeadowsMark Randall MeadowsThe Hill's Morning Report - Presented by Mastercard - Congress inches closer to virus relief deal Alyssa Farah resigns as White House communications director Trump hits Barr over voter fraud remarks: 'He hasn't looked' MORE in an October phone call to not interfere with the FDA approval process. 

“The White House did exactly what I had urged,” the senator argued. “They respected those decisions and did not change a word. The governors of New York and California should show the same respect to the FDA career scientists that the White House did.” 

This comes as several pharmaceutical companies are conducting late-stage trials for coronavirus candidate vaccines. 

On Friday, AstraZeneca announced that the FDA had allowed the company to restart its phase three COVID-19 vaccine trial in the U.S. just days after a volunteer in the company’s Brazil trial died. 

Johnson & Johnson also announced on Friday that it is preparing to restart its trial following consultation with the FDA.

The company became the second to pause its trial earlier this month after a person suffered an “unexplained illness,” although it said in a statement that there was "no evidence that the vaccine caused the event." 

While Trump suggested in Thursday’s presidential debate that a COVID-19 vaccine could be available in a matter of weeks, experts have said one likely will not be available for public use until well into 2021.